Abstracts from the 17th European Headache Congress (EHC)

Specifically, we observed an increasing trend in risk of migraine as COVID-19 genetically increased (β = 0.298, 95% confidence interval [CI]: 1.015-1.790, p = 0.039), and the data were robust without obvious bias.

also in 38,133 other papers

Conclusion: Atogepant demonstrated nominally significant reduction of migraine-related disability, including absenteeism and presenteeism; improved work productivity; reduced activity impairment; and greater global impression of change among people with EM and prior inadequate response to 2–4 classes of OMPMs.

also in 4,806 other papers

In the small subgroup taking preventive medication, response rates for pain freedom at 2 h were greater for rimegepant than placebo (18.4% vs 0%, respectively; P =0.0103); for freedom from the MBS at 2 h the difference between rimegepant and placebo (57.9% vs 37.1%; P =0.0726) showed similar trends but did not reach statistical significance (Figure).

also in 75,868 other papers

There was a clear trend of decreasing headache severity, intensity, duration, NRS and frequency from six months to 12 months.

also in 12,254 other papers